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Abstract In Xenopus oocyte, the formation of complexes
between neosynthesized cyclins and Cdc2 contributes to Cdc2
kinase activation that triggers meiotic divisions. It has been
proposed that cytoplasmic membranes could be involved in this
process. To investigate this possibility, we have injected in the
oocyte two undegradable human cyclin A2 mutants anchored to
the endoplasmic reticulum (ER) membrane. They encode fusion
proteins between the truncated cyclin A2-v152 and a viral or
cellular ER-targeting domain. We show that both mutants are
fully functional as mitotic cyclins when expressed in Xenopus
oocytes, bind Cdc2 and activate M-phase promoting
factor. ß 2001 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
Cyclins play an essential role in progression through the
eukaryotic cell cycle, acting as regulatory subunits of cyclin-
dependent kinases (CDKs). CDK^cyclin complexes control
cell cycle progression by phosphorylating regulatory proteins.
A- and B-type cyclins are more speci¢cally responsible for the
onset of mitosis, and, through their degradation, the exit from
mitosis. Their activities are mediated by changes in their sub-
cellular localization during successive phases of the cell cycle.
The meiotic maturation of Xenopus oocytes represents an
excellent model for studying the G2^M transition of the cell
cycle, especially the regulation of the mitotic cyclins and their
CDK partner, Cdc2. In response to progesterone, prophase-
blocked oocytes re-enter the cell cycle by activating the uni-
versal mitotic kinase, the cyclin B^Cdc2 complex, also called
MPF for M-phase promoting factor. Resting prophase oo-
cytes contain a stockpile of cyclin B^Cdc2 complexes, called
pre-MPF, that are maintained inactive by two inhibitory
phosphorylations of the Thr14 and Tyr15 residues of Cdc2
[1]. These inhibitory phosphorylations are catalyzed by the
Myt1 kinase [2]. The Cdc25 phosphatase acts antagonistically
to Myt1 by catalyzing the dephosphorylation of both inhib-
itory residues of Cdc2 [3,4]. In response to progesterone, MPF
is activated by a two-step mechanism involving a positive
feedback loop known as auto-ampli¢cation [5]. A small
amount of active MPF is ¢rst generated. It acts as a trigger,
contributing to the activation of Cdc25 and consequently to
the conversion of the pre-MPF store into active MPF. The
mechanism of the formation of the triggering activity of Cdc2
is not clearly elucidated, although it probably involves the
synthesis of new Cdc2 partners [6], such as cyclins or the
RINGO/Speedy proteins [7^9]. These proteins would recruit
monomeric Cdc2 molecules, which are present in large excess
over the pre-MPF molecules [10]. The neoformed complexes
would escape Myt1 phosphorylation and would be directly
active as trigger, to initiate the auto-ampli¢cation mechanism.
This model is supported by many experimental data, including
injection of ectopic mitotic cyclins, A- or B-types, known to
induce rapidly Cdc2 activation in the Xenopus oocyte [11,12].
MPF activation occurs in the oocyte cytoplasm. All the
molecular players involved in Cdc2 activation are mainly, if
not exclusively, located in the cytoplasm, and progesterone is
able to trigger MPF activation in enucleated oocytes [5]. Sev-
eral reports support the view that membrane compartments
could be involved in the progesterone transduction pathway
leading to Cdc2 activation. During progesterone-induced mei-
otic maturation, protein tra⁄cking is arrested and the Golgi
apparatus is disorganized [13]. Moreover, drugs that interact
with Golgi membranes and block intracellular membrane traf-
¢cking can release the prophase block and trigger MPF acti-
vation [14,15], implying that intracellular vesicle tra⁄c is
linked with Cdc2 activation. Indeed, several molecules directly
involved in Cdc2 regulation are located in the membranes,
such as Myt1 [2] and a yet unidenti¢ed mitotic Cdc2 inhibitor
[16]. Moreover, it has recently been reported that free Cdc2 is
recovered in association with the external layer of membrane
vesicles, whereas cyclin B2-associated Cdc2 is not [17]. All
these data implicate that in Xenopus oocyte, the newly formed
complexes between free Cdc2 and neosynthesized cyclins
could form at the vicinity of a membrane compartment. How-
ever, it has never been reported that cyclin^Cdc2 complexes
0014-5793 / 01 / $20.00 ß 2001 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 9 2 0 - 9
*Corresponding author. Fax: (33)-1-44 27 34 72.
E-mail address: jessus@ccr.jussieu.fr (C. Jessus).
1 Present address: Service de Biochimie et de Ge¤ne¤tique Mole¤culaire,
Centre d’Etudes de Saclay, 91191 Gif sur Yvette Cedex, France.
2 Present address: UMR-CNRS 7098, Biochimie Cellulaire,
Universite¤ Pierre et Marie Curie, Case 265, 4 Place Jussieu, 75252
Paris Cedex 05, France.
Abbreviations: APC/C, anaphase promoting complex/cyclosome;
CDK, cyclin-dependent kinase; ER, endoplasmic reticulum; GVBD,
germinal vesicle breakdown; MPF, M-phase promoting factor
FEBS 25316 5-10-01
FEBS 25316 FEBS Letters 506 (2001) 243^248
can be recovered in association with membranes, and that
such complexes can be active, as expected from the threshold
activity initiating MPF ampli¢cation in the oocyte.
In order to test this hypothesis, we took advantage of our
previous identi¢cation of a mutant cyclin A2 in a human
hepatitis B virus (HBV)-induced hepatoma [18]. The mutant
protein, called S2A, consists of the N-terminal 156 residues of
the PreS2/St HBV envelope protein fused to the C-terminal
280 residues of cyclin A2, a region that includes the cyclin box
but is devoid of the sequence responsible for cyclin degrada-
tion through the anaphase promoting complex/cyclosome
(APC/C) ubiquitin pathway. S2A is constitutively localized
to the endoplasmic reticulum (ER) membranes through its
viral PreS2/St HBV portion. Interestingly, it is endowed
with a transforming activity [19], suggesting that both the
stabilization and the ER location of the cyclin would be su⁄-
cient to lead to oncogenic activation. We also constructed
another chimeric cyclin A2 protein (PRL-A2), addressed to
ER by a cellular targeting domain. PRL-A2 consists of cyclin
A2 deleted of its N-terminal 152 amino acids (A2-v152) and
fused to an ER-targeting domain, PRL, containing the pro-
lactin signal peptide in frame with an IgM stop transfer se-
quence [20]. We established that cyclin A2-v152 targeted to
the ER by either the viral (PreS2/St in S2A) or cellular (PRL
in PRL-A2) domain is fully functional, and acting as a mitotic
cyclin when microinjected in Xenopus oocytes. Both proteins
bind Cdc2 in ovo and trigger MPF activation.
2. Materials and methods
2.1. Materials
Xenopus laevis adult females (CNRS, Rennes, France) were bred
and maintained under laboratory conditions. [Q-32P]ATP and
[35S]methionine were obtained from NEN. Reagents, unless otherwise
speci¢ed, were from Sigma.
2.2. Plasmid constructs
pSP cyclin A2-v152 and pSP cyclin A2-v152m vectors were ob-
tained by cloning the cyclin A2-v152 EcoRI/SacI fragment and its
corresponding mutant in the MRAIL motif into the EcoRI/SacI sites
of pSP Sp1L.ST.gG plasmid, which encodes an ER-targeting do-
main, allowing proteins to become embedded in the lipid bilayer
[20]. It contains the signal peptide and the ¢rst amino acid of bovine
prolactin, followed by the L-lactamase sequence and the mouse IgM
heavy chain stop transfer sequence. All reading frames were veri¢ed
by direct sequencing.
2.3. Xenopus oocyte treatment and extract preparation
Fully grown Xenopus oocytes were isolated and prepared as previ-
ously described [1]. Meiotic maturation was induced by 1 WM proges-
terone. Oocytes were microinjected with 50 ng mRNAs. They were
also injected with 35S-labeled A2-v152, S2A and S2Am proteins in the
presence of 100 Wg/ml cycloheximide in the external medium. Germi-
nal vesicle breakdown (GVBD) was assessed by the appearance of a
characteristic white spot at the animal pole and oocyte dissection. At
various times after injection or addition of progesterone, oocytes were
collected and frozen at 380‡C. Oocytes were then lysed at 4‡C in four
volumes of EB (80 mM L-glycerophosphate pH 7.3, 20 mM EGTA,
15 mM MgCl2, 1 mM dithiothreitol) supplemented with protease in-
hibitors: 25 Wg/ml leupeptin and aprotinin, 10 Wg/ml pepstatin, 1 mM
benzamidine, 1 WM AEBSF (Pentapharm AG). To visualize the elec-
trophoretic shift of Cdc25, 1 mM orthovanadate was included in EB.
Lysates were centrifuged at 5000Ug for 3 min at 4‡C (Sigma 302K
centrifuge). The supernatant was harvested and analyzed. For subcel-
lular fractionation, oocyte extracts were made in high-salt EB (0.5 M
NaCl) and the supernatant obtained at 5000Ug was further centri-
fuged at 100 000Ug for 1 h at 4‡C, leading to a supernatant (soluble
proteins) and a membrane pellet. The pellet was washed in high-salt
EB and ultracentrifuged again. Both fractions were analyzed by im-
munoblot.
2.4. Histone H1 kinase assay
Extracts (equivalent to ¢ve oocytes) were collected for p13suc1 bind-
ing and the histone H1 kinase activity associated with the beads was
assayed as described [1].
2.5. mRNAs preparation and in vitro transcription^translation
Wild-type cyclin A2, cyclin A2-v152, S2A, S2Am, PreS2/St, PRL-
A2 and PRL-A2m mRNAs containing a 5P,7-methyl-guanosine cap
were synthesized using the Riboprobe in vitro Transcription System
(Promega). The mRNA pellets were resuspended in RNase-free water
at a concentration of 1 Wg/Wl, and then stored at 320‡C until further
use. In vitro transcription^translation of pBS plasmids containing
human cyclin A2-v152, S2A and S2Am cDNAs was performed in
the presence of [35S]methionine using the TNT reticulocyte lysate kit
(Promega).
2.6. Western blot analysis and antibodies
Equal amounts of oocyte extracts (equivalent of two oocytes per
lane) were separated on 12% SDS^PAGE, transferred on nitrocellu-
lose (Schleicher and Schuell) and processed for immunoblotting. The
following primary antibodies were used: sheep polyclonal anti-Xeno-
pus cyclin B2 [21], rabbit polyclonal anti-Xenopus Cdc25 [22], mouse
monoclonal anti-Xenopus Cdc2 [23] and rabbit polyclonal anti-human
cyclin A2 raised against the C-terminal region, CHLA-4 [24]. The
appropriate horseradish peroxidase-conjugated secondary antibodies
were used (Jackson Immunoresearch). The chemoluminescence re-
agent was obtained from NEN.
3. Results
3.1. Description of the various cyclin A forms used in this study
In order to investigate whether a membrane-associated cy-
clin A2 was functional, we used the chimeric proteins PRL-A2
and S2A sketched in Fig. 1. These proteins are deleted from
152 residues in the cyclin A2 N-terminal region, and therefore
lack the cyclin A2 N-terminal degradation signal [25]. Both
proteins are targeted to the ER membrane, the cyclin A2
portion being on the cytosolic side. The principal di¡erence
between S2A and PRL-A2 is the nature of the amino-terminal
ER-targeting portion, respectively viral: PreS2/St, or cellular:
PRL. The viral and cellular ER-targeting domains contain
respectively 156 and 179 amino acids, so the chimeric proteins
have a molecular weight similar to the full-length wild-type
cyclin A2. So as to determine whether the function of S2A
and PRL-A2 relies on binding to a CDK, we also constructed
MRAIL to MAAIL point mutants of S2A and PRL-A2 in-
capable of binding CDKs, and referred to as S2Am and PRL-
A2m, respectively. The cyclin A2-v152 moiety, which is
strictly nuclear and undegradable, was used as a comparison.
3.2. ER-targeted cyclin A2-v152 functions as a mitotic cyclin in
Xenopus oocytes
We examined whether the expression of cyclin A2-v152
targeted to the ER was able to induce the meiotic maturation
of Xenopus oocytes. Capped mRNAs encoding the di¡erent
proteins described in Fig. 1 were microinjected into prophase-
blocked Xenopus oocytes. We then analyzed the percentage of
oocytes having undergone GVBD and assayed the histone H1
kinase activity of Cdc2 (Fig. 2). As expected, wild-type cyclin
A2 and A2-v152 caused GVBD and Cdc2 activation. Both
S2A and PRL-A2 induced GVBD with the same time-course
as wild-type cyclin A2 and A2-v152, within 3 h after injection,
in parallel with the induction of a signi¢cant increase in the
H1 kinase activity of Cdc2, already maximal 2 h after injec-
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tion (Fig. 2). It has to be noted that A2-v152 induced a
stronger and more stable Cdc2 activity than that of other
forms, probably due to a higher stability of the protein (see
below). The S2Am and PRL-A2m point mutants were com-
pletely inactive, as were the viral moiety of S2A (PreS2/St)
and the ER-targeting domain PRL, which are unable to
bind to and activate a CDK (Fig. 2 and data not shown).
This demonstrates that the activity of S2A and PRL-A2 de-
pends on their binding to Cdc2. We ascertained that all the
expressed cyclin A2 proteins, except PRL-A2m and S2Am,
were bound to Cdc2 by immunoblotting isolated p13suc1-
bound Cdc2 with an anti-cyclin A2 antibody (data not
shown).
3.3. Ectopically expressed PRL-A2 and S2A cyclins trigger
MPF auto-ampli¢cation in Xenopus oocytes
The Cdc2 activity generated by the injection of A-type cy-
clins may be solely due to the formation of ectopic complexes
between Xenopus Cdc2 and cyclin A2. Alternatively, the neo-
formed cyclin A2^Cdc2 complexes may be capable of trigger-
ing the activation of endogenous cyclin B2^Cdc2 complexes
(i.e. pre-MPF), initiating the positive feedback loop known as
MPF auto-ampli¢cation in Xenopus oocytes. To address this
question, we monitored the phosphorylation states of Cdc2,
its regulatory subunit cyclin B2 and its activating phosphatase
Cdc25 by immunoblot after injection of oocytes with the var-
ious cyclin A mRNAs (Fig. 2). Cdc2 migrated as a single
band, corresponding to the active dephosphorylated form of
the kinase, in the oocytes that had matured following proges-
terone treatment or microinjection with the various active
cyclins, namely wild-type A2, A2-v152, S2A and PRL-A2
(Fig. 2). In contrast, prophase-blocked oocytes or oocytes
microinjected with the inactive mutants S2Am and PRL-
A2m exhibited the Cdc2 doublet, representative of the inactive
Cdc2 forms (the upper band corresponding to tyrosine-phos-
phorylated Cdc2 bound to cyclin B, or pre-MPF, and the
lower band to unphosphorylated monomeric Cdc2). Accord-
ingly, cyclin B2 phosphorylation, visualized by the transition
of a doublet to a single upper band, and mitotic activatory
phosphorylation of Cdc25, visualized by a large shift in its
electrophoretic mobility, were speci¢cally observed in the sam-
ples containing active Cdc2 (Fig. 2). In contrast, phosphory-
lation of cyclin B2 and Cdc25 was detected neither in oocytes
injected with S2Am and PRL-A2m nor in immature oocytes.
Taken together, these experiments demonstrate that S2A and
PRL-A2 are fully functional in vivo. These constructs recruit
and activate Cdc2 in the vicinity of ER membranes, and are
able to trigger MPF activation.
3.4. ER-targeted cyclin A2-v152 is stable in Xenopus oocytes
In order to analyze the expression levels of ectopically ex-
pressed cyclins A2 in Xenopus oocytes, batches of oocytes
Fig. 1. Sketches of the di¡erent constructs used in this study. Black
box: highly conserved central cyclin box. Cyclin A2: full-length hu-
man cyclin A2 protein. N-terminal degradation signal: hatched. Cy-
clin A2-v152: carboxy-terminal portion of cyclin A2 lacking the 152
amino acids of the N-terminus. S2A: chimeric protein resulting
from the fusion of A2-v152 to PreS2/St, a truncated middle enve-
lope protein of HBV (residues 1^156), in which the 55-amino acid
PreS2 domain is fused to the 101-amino acid truncated S domain
(gray). S2Am: MRAIL to MAAIL S2A mutant unable to bind
CDKs. PRL-A2: protein resulting from the fusion of A2-v152 to
the ER-targeting domain PRL (hatched). PRL-A2m: MRAIL to
MAAIL PRL-A2 mutant unable to bind CDKs.
Fig. 2. ER membrane-targeted cyclin A2 induces GVBD and MPF
activation in vivo. Capped mRNAs encoding various forms of cy-
clin A2 were injected into oocytes (30 oocytes per construct). His-
tone H1 kinase activity of Cdc2 was assayed at the indicated times
after injection. GVBD was scored 5 h after injection. At the time of
GVBD, mRNA-injected oocytes were lysed, and then centrifuged at
100 000Ug. The supernatants were analyzed by immunoblotting
with anti-Cdc2, anti-cyclin B2 and anti-Cdc25C antibodies. Pg: pro-
gesterone-treated oocytes; prophase: untreated oocytes. Three sepa-
rate experiments gave identical results.
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were lysed at di¡erent times after the microinjection of
mRNAs, and cyclin A2 proteins were detected by immunoblot
(Fig. 3A). An antibody directed against human cyclin A that
does not recognize Xenopus cyclin A was used. S2A, PRL-A2,
and A2-v152 appeared to be translated within the ¢rst hour
following mRNAs injection, and then accumulated during
meiotic maturation ^ GVBD was initiated at 2 h after injec-
tion and completed at 5 h in this typical experiment (Fig. 3A).
This observation is consistent with the absence of the N-ter-
minal degradation signal in the three constructs giving rise to
stabilized proteins. In vitro translated S2A appeared as a
doublet of bands corresponding to the alternative use of
two functional AUG codons for translation initiation in the
open reading frame. When translated in the oocyte, S2A ap-
peared as a triplet of bands with an increased apparent mo-
lecular weight. This is most probably due to glycosylation
occurring post-translationally into an asparagine-linked glyco-
sylation site (Asn4) present in the PreS2/St region. The ex-
pression levels of the mutant forms S2Am and PRL-A2m
were weaker (Fig. 3A and data not shown). As expected,
wild-type cyclin A2 containing a degradation signal and rep-
resenting an APC/C target was transiently accumulated at the
time of GVBD (data not shown).
We next addressed the question of the instability of the
PRL-A2m and S2Am mutants, which cannot bind Cdc2 and
do not possess a degradation signal. In vitro translated 35S-
labeled S2A, S2Am and A2-v152 proteins were injected into
prophase oocytes in the presence of cycloheximide, to prevent
protein synthesis. Under these conditions, the amount of mi-
croinjected proteins was insu⁄cient to induce meiotic matu-
ration (not shown). Oocytes were lysed at di¡erent times after
injection, and radioactive proteins were monitored by auto-
radiography (Fig. 3B). A2-v152 was highly stable, exhibiting
no degradation during the time-course of the experiment. S2A
showed a half-life of 18 h, whereas S2Am was very unstable
with a half-life of 15 min. PRL-A2 and PRL-A2m stability
was comparable to the stability of S2A and S2Am, respec-
tively (data not shown). Thus, the mutation in the MRAIL
motif that prevents Cdc2 binding, targets the protein to
degradation through a pathway distinct from the APC/C
ubiquitin pathway, which is inactive in prophase oocytes
[26,27].
3.5. PRL-A2 and S2A proteins are membrane-associated in
Xenopus oocytes
In order to con¢rm that both PreS2/St and PRL, the ER-
targeting signals, are functional in Xenopus oocytes, and thus
that the observed activities were actually due to cyclin A2
anchored to the ER, subcellular fractionation was performed.
Oocytes were microinjected with the various capped mRNAs
and lysed 1 h after injection, when in vivo synthesis of the
proteins and Cdc2 activation were initiated, but before
GVBD. Lysates were centrifuged for 1 h at 100 000Ug. The
supernatant (soluble proteins) and pellet (membrane proteins)
were analyzed by immunoblot using an anti-cyclin A2 anti-
body. Fig. 4 shows that S2A and PRL-A2 as well as the
corresponding mutants were recovered in the membrane frac-
tion although their modes of insertion into the ER membrane
are di¡erent (cotranslational for PRL-A2 and post-transla-
tional for S2A). In contrast to S2A, S2Am and PRL-A2m,
which are exclusively recovered with membranes, a minor
fraction of the PRL-A2 protein (around 5%) was detected in
the supernatant in this particular experiment, probably result-
ing from a membrane contamination since this was not repro-
ducibly observed. Cyclin A2-v152, which was expected to be
cytosolic and did not contain any exposed hydrophobic do-
main, was equally distributed in both the soluble and mem-
brane fractions, in two independent experiments, despite the
high ionic strength of the lysate bu¡er. The presence of cyclin
A2-v152 in the membrane fraction may be due to its recruit-
ment by free monomeric Cdc2, which exhibits a strong a⁄nity
for oocyte membranes [17]. The distribution of the various
cyclin A2 forms did not vary from 1 to 7 h after injection
(data not shown). According to the presence of S2A and
PRL-A2 in the membranes, histone H1 kinase activity can
be measured in the membrane pellets starting 2 h after the
corresponding mRNAs injection (data not shown).
Fig. 3. ER membrane-targeted cyclin A2 forms are stable and accu-
mulate in oocytes whereas the inactive mutants are unstable. A:
Capped mRNAs encoding various forms of cyclin A2 were injected
into oocytes. Oocytes were lysed at the indicated times after injec-
tion of mRNAs. Proteins were analyzed by immunoblot using an
anti-cyclin A2 antibody. Arrows: in vitro translated cyclins used as
molecular weight markers (crude labeled reticulocyte lysate: RL). B:
Prophase oocytes were injected with the indicated in vitro translated
35S-labeled proteins in the presence of cycloheximide, and lysed at
the indicated times after injection. Proteins were separated by gel
electrophoresis and autoradiographed.
Fig. 4. S2A, PRL-A2 and the corresponding mutants are associated
with membranes in Xenopus oocytes. Anti-cyclin A2 immunoblot of
cytosolic (supernatant) and membrane (pellet) fractions. Oocytes
matured by incubation with progesterone (Pg) or injected with the
indicated capped mRNAs were lysed in high-salt EB 1 h later. Two
oocytes were loaded in each lane.
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4. Discussion
We have shown that cyclin A2 anchored to the ER mem-
brane by a cellular or viral signal peptide functions as a mi-
totic cyclin. PRL-A2, as well as S2A, recruits and activates
cyclin A2-dependent kinase in the vicinity of the ER mem-
brane, indicating that folding of the membrane-anchored pro-
tein and the biochemical micro-environment existing near the
membrane are favorable to the binding and activation of
Cdc2, and to subsequent triggering of MPF activation. The
presence of active cyclin A-dependent kinase in the cytoplas-
mic membranes has already been described in the particular
case of regenerating liver cells. In such cells, cyclin A^CDK2
complexes have been found not only in the nucleus, but also
in the cytoplasm, speci¢cally in the microsomal and endocytic
compartments, and exhibited histone H1 kinase activity
[28,29].
It has been shown previously that cyclin A microinjected
into G2-arrested Xenopus oocytes activates MPF [11,30,31].
Our results show that ER-targeted A2 cyclins are also able
to induce meiotic maturation and activate MPF through their
binding to Cdc2, despite their membrane insertion. In G2-
blocked oocytes, Cdc2 exists in two inactive states: a major
monomeric form that is not bound to any cyclin, and a Tyr15/
Thr14 phosphorylated form that is associated with cyclin B2
and represents inactive ‘pre-MPF’ [10]. Myt1 kinase is respon-
sible for the inhibitory phosphorylations of Cdc2 in the rest-
ing prophase oocyte [2]. The activation of MPF by cyclin
injection therefore requires Myt1 down-regulation. In agree-
ment with previous reports, our present work suggests that an
excess of cytoplasmic cyclin A2, either cytosolic or membrane-
associated, promotes entry into meiotic division by bypassing
or suppressing the inhibitory potential of Myt1. A simple
explanation is that free Cdc2 binds to the ectopically ex-
pressed cyclin A2, leading to an excess of cyclin A2^Cdc2
complexes, which are able to escape the inhibitory activity
of Myt1. Moreover, cyclin A2^Cdc2 complexes have been
shown to be poorly sensitive to Tyr15 phosphorylation [32].
These observations explain why injection of cyclin A2 can
generate active complexes after endogenous monomeric
Cdc2 recruitment. Once some Cdc2 kinase activity is gener-
ated, it leads to endogenous Cdc2^cyclin B2 activation by
inducing the positive feedback loop known in amphibian oo-
cytes as MPF auto-ampli¢cation [5]. This complex mechanism
relies on both Myt1 inactivation and Cdc25 activation, and
can be initiated by a threshold of either cyclin A^ or cyclin B^
Cdc2 complexes [33]. Our study demonstrates for the ¢rst time
that active cyclin^Cdc2 complexes can be formed in associa-
tion with membranes, and are then able to induce all the
machinery supporting MPF ampli¢cation through the activa-
tion of cytoplasmic soluble Cdc25 phosphatase. It has been
reported that monomeric Cdc2 exhibits high a⁄nity for oo-
cyte membranes [17]. Moreover, progesterone induces a rear-
rangement of the ER and Golgi membranes [13]. Interestingly,
several drugs known to alter the intracellular membrane traf-
¢cking can release the prophase block and trigger MPF acti-
vation [14,15], showing the importance of the intracellular
membrane turn-over in meiotic maturation. Therefore, it
can be proposed that the threshold of MPF activity physio-
logically generated by progesterone and responsible for entry
into the ¢rst meiotic division, may form at the ER membrane
level. The hormone would favor the association between
membrane-located monomeric Cdc2 and cyclin B both by
remodeling the intracellular membranes and by promoting
cyclin B synthesis independently of MPF, as already reported
[7]. Protein fusion using the PRL or PreS2/St domain applied
to di¡erent molecular players involved in MPF activation in
the oocyte in order to target them to the ER may be of value
to assessing the physiological relevance of this model.
Another interesting feature of our results came of the use of
cyclin A2 proteins point-mutated in the MRAIL motif, so
they cannot bind Cdc2. As expected, these mutants are unable
to trigger meiotic maturation, demonstrating that the ER-tar-
geted cyclin A2 forms are active by recruiting free Cdc2 in the
oocyte. Unexpectedly, despite the deletion of the N-terminal
sequences, known to stabilize mitotic cyclins [25], these mu-
tants exhibit a short half-life (about 15 min) when expressed
in the prophase oocyte. This implies that a proteolytic machi-
nery, which does not depend on the APC-mediated ubiquiti-
nation (the N-terminal degradation signal is missing and APC
is inactive in prophase oocytes), degrades free cyclins. Indeed,
Cdc2 is stoichiometrically 10 times more abundant than cy-
clins in the oocyte [10]. An excess of cyclins could represent a
pathological situation, corrected by a kind of checkpoint
mechanism that recognizes and eliminates by degradation
the Cdc2-non-bound cyclin molecules.
Acknowledgements: We thank all the members of our two laborato-
ries for helpful discussions, especially V. De Smedt, O. Haccard and
R. Ozon. We are grateful to Dr. D. Beach for providing the p13
overexpressing Escherichia coli strain, to Dr. T. Hunt for the anti-
Cdc2 antibody, to Dr. J. Maller for the anti-cyclin B2 and anti-
Cdc25C antibodies, to Dr. V.R. Lingappa for pSP Sp1L.ST.gG
cDNA. This research was supported by Grants from INSERM,
CNRS, INRA, Universite¤ Pierre and Marie Curie, ARC (no. 5899
to C.J., no. 9169 to J.S.-T. and C.B.), LNCC.
References
[1] Jessus, C., Rime, H., Haccard, O., Van, L.J., Goris, J., Merle-
vede, W. and Ozon, R. (1991) Development 111, 813^820.
[2] Mueller, P.R., Coleman, T.R., Kumagai, A. and Dunphy, W.G.
(1995) Science 270, 86^90.
[3] Gautier, J., Solomon, M.J., Booher, R.N., Bazan, J.F. and
Kirschner, M.W. (1991) Cell 67, 197^211.
[4] Dunphy, W.G. and Kumagai, A. (1991) Cell 67, 189^196.
[5] Masui, Y. and Markert, C.L. (1971) J. Exp. Zool. 177, 129^146.
[6] Nebreda, A., Gannon, J. and Hunt, T. (1995) EMBO J. 14,
5597^5607.
[7] Frank-Vaillant, M., Jessus, C., Ozon, R., Maller, J.L. and Hac-
card, O. (1999) Mol. Biol. Cell 10, 3279^3288.
[8] Ferby, I., Blazquez, M., Palmer, A., Eritja, R. and Nebreda,
A.R. (1999) Genes Dev. 13, 2177^2189.
[9] Lenormand, J.L., Dellinger, R.W., Knudsen, K.E., Subramani,
S. and Donoghue, D.J. (1999) EMBO J. 18, 1869^1877.
[10] Kobayashi, H., Minshull, J., Ford, C., Golsteyn, R., Poon, R.
and Hunt, T. (1991) J. Cell Biol. 114, 755^765.
[11] Swenson, K.I., Farrell, K.M. and Ruderman, J.V. (1986) Cell 47,
861^870.
[12] Murray, A.W. (1987) Nature 326, 542^543.
[13] Colman, A., Jones, E.A. and Heasman, J. (1985) J. Cell Biol.
101, 313^318.
[14] De Smedt, V., Rime, H., Jessus, C. and Ozon, R. (1995) FEBS
Lett. 375, 249^253.
[15] Mulner-Lorillon, O., Belle, R., Cormier, P., Drewing, S., Minella,
O., Poulhe, R. and Schmalzing, G. (1995) Dev. Biol. 170, 223^
229.
[16] Lee, T.H. and Kirschner, M.W. (1996) Proc. Natl. Acad. Sci.
USA 93, 352^356.
[17] De Smedt, V., Crozet, N. and Jessus, C. (1999) Microsc. Res.
Tech. 45, 13^30.
FEBS 25316 5-10-01
J. Faivre et al./FEBS Letters 506 (2001) 243^248 247
[18] Wang, J., Chenivesse, X., Henglein, B. and Brechot, C. (1990)
Nature 343, 555^557.
[19] Berasain, C., Patil, D., Perera, E., Huang, S.M., Mouly, H. and
Brechot, C. (1998) Oncogene 16, 1277^1288.
[20] Yost, C.S., Hedgpeth, J. and Lingappa, V.R. (1983) Cell 34, 759^
766.
[21] Gautier, J., Minshull, J., Lohka, M., Glotzer, M., Hunt, T. and
Maller, J.L. (1990) Cell 60, 487^494.
[22] Izumi, T., Walker, D.H. and Maller, J.L. (1992) Mol. Biol. Cell
3, 927^939.
[23] Kobayashi, H., Stewart, E., Poon, R.Y.C. and Hunt, T. (1994)
J. Biol. Chem. 269, 29153^29160.
[24] Hall, F.L., Braun, R.K., Mihara, K., Fung, Y.-K.T., Berndt, N.,
Carbonaro-hall, D.A. and Vulliet, P.R. (1991) J. Biol. Chem.
266, 17430^17440.
[25] Jacobs, H.W., Keidel, E. and Lehner, C.F. (2001) EMBO J. 20,
2376^2386.
[26] Gross, S.D., Schwab, M.S., Taieb, F.E., Lewellyn, A.L., Qian,
Y.W. and Maller, J.L. (2000) Curr. Biol. 10, 430^438.
[27] Peter, M., Castro, A., Lorca, T., Le Peuch, C., Magnaghi-Jaulin,
L., Doree, M. and Labbe, J.C. (2001) Nat. Cell Biol. 3, 83^87.
[28] Castro, A., Jaumot, M., Verges, M., Agell, N. and Bachs, O.
(1994) Biochem. Biophys. Res. Commun. 201, 1072^1078.
[29] Verges, M., Castro, A., Jaumot, M., Bachs, O. and Enrich, C.
(1997) Biochem. Biophys. Res. Commun. 230, 49^53.
[30] Roy, L.M., Swenson, K.I., Walker, D.H., Gabrielli, B.G., Li,
R.S., Piwnica-Worms, H. and Maller, J.L. (1991) J. Cell. Biol.
113, 507^514.
[31] Rime, H., Jessus, C. and Ozon, R. (1995) Exp. Cell Res. 219, 29^
38.
[32] Clarke, P., Leiss, D., Pagano, M. and Karsenti, E. (1992) EMBO
J. 11, 1751^1761.
[33] Taieb, F., Thibier, C. and Jessus, C. (1997) Mol. Reprod. Dev.
48, 397^411.
FEBS 25316 5-10-01
J. Faivre et al./FEBS Letters 506 (2001) 243^248248
